Indications |
Intravenous Short-term management of severe heart failure, Acutely decompensated heart failure Adult: Initially, a loading dose of 50 mcg/kg by slow IV injection over 10 min then continuous maintenance infusion of 0.375-0.75 mcg/kg/min. Adjust according to haemodynamics and clinical response. Max dose 1.13 mcg/kg/day. Child: Initial loading dose of 75 mcg/kg by IV injection over 10-60 min followed by continuous infusion of 0.5-0.75 mcg/kg/min.
Special Populations: Dose reduction in patients with renal impairment. Reconstitution: Use 0.45% sodium chloride, 0.9% sodium chloride or 5% dextrose inj as diluents. Incompatibility: Y-site incompatibility: Imipenem-cilastin, furosemide, procainamide. Syringe incompatibility: Furosemide. Admixture incompatibility: Furosemide, procainamide, bumetanide. |
||||||||||||||
Contraindications |
Heart valve stenosis, acute myocardial infarction. | ||||||||||||||
Warnings / Precautions |
Severe obstructive aortic or pulmonary valvular disease, hypertrophic cardiomyopathy, atrial flutter or fibrillation. Monitor blood pressure, heart rate, ECG, fluid and electrolyte balance. Pregnancy and lactation. Use for >48 hr. | ||||||||||||||
Adverse Reactions |
Angina-like chest pain, headache, hypokalaemia, tremor, thrombocytopenia, bronchospasm. Potentially Fatal: Supraventricular and ventricular arrhythmias; hypotension. |
||||||||||||||
Drug Interactions |
Potentially Fatal: Avoid anagrelide due the potential for increased inotropic effects. See Below for More milrinone Drug Interactions |
||||||||||||||
Mechanism of Actions |
Milrinone is a selective phosphodiesterase III inhibitor with positive inotropic and vasodilator activity. It selectively inhibits cyclic adenosine monophosphate (cAMP) phosphodiesterase activity in cardiac and vascular muscles resulting in increased intracellular concentrations of cAMP. It also acts directly on vascular smooth muscle. Onset: IV: 5-15 minutes. Distribution: Protein binding: About 70%. Volume of distribution at steady-state: 0.32-0.45 L/kg. Metabolism: About 12% metabolised hepatically. Excretion: Eliminated via urine (85% as unchanged drug). Elimination half life: About 2.5 hr. |
||||||||||||||
Storage Conditions |
Intravenous: Store at 15-30°C. | ||||||||||||||
ATC Classification |
C01CE02 - milrinone ; Belongs to the class of phosphodiesterase inhibitors. Used in the treatment of heart failure. | ||||||||||||||
Storage |
Intravenous: Store at 15-30°C. | ||||||||||||||
Available As |
|
Milrinone
Post Review about Milrinone Click here to cancel reply.
Milrinone Containing Brands
Milrinone is used in following diseases
Drug - Drug Interactions of Milrinone
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.